Factor H and Factor I are the principal fluid‑phase regulators that shut down the alternative complement pathway. Factor H simultaneously blocks formation of the alternative C3 convertase (C3bBb) and acts as a cofactor for Factor I – a serine protease that cleaves and permanently inactivates C3b. On the surface of host cells, decay‑accelerating factor (DAF/CD55) provides an additional layer of protection by forcibly dissociating the Bb catalytic subunit from the convertase. Together, these proteins prevent runaway amplification and bystander tissue damage, and their purified forms are essential raw materials in diagnostic assays.
Diagnosing complement‑driven diseases such as atypical hemolytic uremic syndrome (aHUS), age‑related macular degeneration, or paroxysmal nocturnal hemoglobinuria relies on functionally intact, high‑purity Factor H, Factor I, and DAF. These regulators serve as calibration standards, positive controls, and direct immunoassay targets, enabling labs to quantify dysregulation, map pathway activity, and validate drug efficacy.
The Key Inhibitors: Factor H, Factor I, and DAF
Factor H: The Master Fluid‑Phase Regulator
Factor H is a soluble glycoprotein that patrols the circulation and restricts alternative pathway activation to activator surfaces.
It performs two critical functions:
- Decay acceleration – Factor H binds to the alternative C3 convertase (C3bBb) and displaces the catalytic Bb fragment, halting further C3 cleavage.
- Cofactor activity – It presents C3b to Factor I in a conformation that allows Factor I to proteolytically clip C3b into an inactive fragment (iC3b), marking it for phagocytosis.
Without sufficient Factor H activity, the alternative pathway turns into a self‑amplifying loop that damages glomerular basement membranes, retinal pigment epithelium, and vascular endothelium.
Factor I: The Proteolytic Silencer
Factor I is the only complement protease that permanently eliminates C3b function.
It circulates as an active enzyme but is completely useless without a cofactor. Factor H and membrane‑bound cofactors like MCP (CD46) hold C3b in the correct orientation so Factor I can make two sequential cuts, yielding iC3b.
This irreversible event is the definitive off‑switch for the alternative pathway. Consequently, Factor I deficiency leads to uncontrolled C3 consumption and secondary immune deficiency, making it a high‑priority analyte in complement diagnostic panels.
Decay-Accelerating Factor (DAF/CD55): The Host Cell Shield
While Factor H handles the fluid phase, DAF is a GPI‑anchored protein that protects individual cells.
DAF accelerates the dissociation of both the classical and alternative pathway C3 convertases. On the alternative pathway side, it physically wrests the Bb subunit away from C3b on the same membrane, instantly shutting down local convertase activity.
This check is essential because spontaneous “tick‑over” C3 hydrolysis can occur anywhere. DAF ensures that any errant C3bBb assembly on a host cell is rapidly dismantled before amplification can begin.
The Role of Regulatory Proteins in Diagnostic Assay Design
Calibration Standards and Controls
Functional complement assays demand a known, reproducible activity curve. Recombinant Factor H and Factor I are used as calibrators in turbidimetric or ELISA‑based tests to establish the normal range of complement inhibition.
A well‑characterized, preservative‑free preparation allows laboratories to construct standard curves that detect even minor drops in regulatory function. Without these high‑purity reference materials, inter‑assay variability makes it impossible to distinguish mild deficiency from pre‑analytical sample degradation.
Diagnostic Targets for Complement Dysregulation
A growing number of diseases are linked to mutations or autoantibodies against regulatory proteins.
- aHUS – Loss‑of‑function mutations in Factor H or Factor I, or gain‑of‑function autoantibodies that neutralize Factor H, drive microthrombi and renal failure. Diagnostic kits measure antigenic levels and functional Factor H activity in diluted serum.
- Paroxysmal nocturnal hemoglobinuria (PNH) – Because DAF (and CD59) are GPI‑anchored, clones with defective GPI biosynthesis lack these protective molecules. Flow cytometry tests that directly stain for DAF on erythrocytes and granulocytes are the gold standard for PNH diagnosis.
- C3 glomerulopathies – Over‑active alternative pathway convertase (often from stabilizing autoantibodies) can be unmasked by measuring C3 breakdown products in the presence versus absence of recombinant Factor H.
Pathway-Specific Assay Development
Pathway discrimination is central to any complement diagnostic. For the alternative pathway, laboratories use ELISA wells coated with bacterial lipopolysaccharide (LPS) and a reaction buffer containing Mg‑EGTA.
EGTA chelates calcium ($Ca^{2+}$) and shuts down the classical and lectin pathways, while leaving magnesium ($Mg^{2+}$) available for the manganese‑dependent alternative convertase. Adding purified Factor H to such an assay serves as a negative control – the readout should drop to background if the Factor H protein is functional and the assay is working correctly.
Understanding the Trade-offs
Even the best regulatory protein raw materials can introduce pitfalls if not handled carefully.
- Purity vs. functionality – Over‑purification can strip necessary cofactors or induce aggregation that mimics inhibitory activity. A preparation that is >95 % pure by SDS‑PAGE may still perform poorly in a functional decay‑acceleration assay if the protein is partially denatured.
- Capturing membrane‑bound regulators – DAF and MCP require careful solubilization strategies if sourced from cells. Recombinant soluble forms (lacking the GPI anchor) may not reflect the true avidity of the natural cell‑surface protein, leading to underestimated protective capacity in diagnostic readouts.
- Lot‑to‑lot variability – Even minor glycoform differences in recombinant Factor H can alter its cofactor efficiency. IVD manufacturers must perform rigorous bridging studies whenever a new batch of regulatory protein is introduced, ensuring calibrator equivalency.
- Cross‑pathway interference – Factor H also binds to C‑reactive protein and other acute‑phase reactants. In whole‑serum assays, elevated acute‑phase proteins can deplete Factor H availability, giving a false impression of complement hyper‑activation unless the assay design accounts for this consumption.
How to Apply This to Your Project
Your choice of regulatory protein targets depends entirely on the specific diagnostic question you need to answer.
- If your primary focus is screening for aHUS or C3 glomerulopathy: Prioritize a robust, functional Factor H assay. Combine antigenic measurement with a decay‑acceleration or cofactor activity test, and include recombinant Factor I as a calibrator to verify the cofactor‑protease axis is intact.
- If your primary focus is building a pathway‑specific functional screening test: Use Mg‑EGTA buffer to isolate the alternative pathway and include a purified Factor H negative‑control well. Validate the assay with sera from patients with known Factor I deficiency to ensure the results collapse when the regulatory protease is absent.
- If your primary focus is diagnosing PNH: Target DAF and CD59 expression via flow cytometry. Use a well‑characterized anti‑DAF monoclonal antibody that binds the complement control protein domains, and cross‑validate with a fluorescently inactive recombinant DAF protein to confirm no interfering autoantibodies are present in the patient sample.
- If your primary focus is developing a novel drug that targets the alternative pathway: Generate recombinant Factor H and Factor I as functional reagent controls. Incorporate them into a plate‑based convertase stabilisation assay to screen candidate molecules for their ability to restore or mimic the natural off‑switch.
Mastering the inhibitory axis of the alternative pathway—Factor H, Factor I, and DAF—turns a complex cascade into a precisely measurable diagnostic signal, and getting the proteins right is the first step toward any reliable complement assay.
Summary Table:
| Regulatory Protein | Mechanism / Primary Function | Diagnostic Assay Relevance |
|---|---|---|
| Factor H | Fluid-phase regulator; displaces Bb (decay acceleration) & acts as a cofactor for Factor I. | Calibrator/standard in ELISAs; key analyte for aHUS/C3G assays; functional control. |
| Factor I | Serine protease; permanently cleaves and inactivates C3b into iC3b. | Reference standard; essential marker for Factor I deficiency & pathway profiling. |
| DAF (CD55) | Membrane-bound regulator; forcibly dissociates Bb catalytic subunit from host cell convertases. | Gold-standard flow cytometry target for Paroxysmal Nocturnal Hemoglobinuria (PNH). |
Accelerate your complement assay development with high-purity, reliable regulatory proteins. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. Whether you are developing calibrators for aHUS panels, screening for PNH, or building novel complement therapeutics, our team is here to support your pipeline. Contact us today to request samples or technical support!